Texlite 500mg Tablet SR 10s

Introduction to Texlite 500mg Tablet SR 10s

Texlite 500mg Tablet SR 10s is a pharmaceutical product in tablet form primarily used to manage excessive bleeding conditions. This medication is formulated to help prevent the breakdown of blood clots, thereby reducing blood loss in various medical situations.

Composition of Texlite 500mg Tablet SR 10s

Texlite 500mg Tablet SR 10s contains Tranexamic Acid (500mg) as its active ingredient. Tranexamic Acid works by inhibiting the enzyme plasmin, which is responsible for dissolving blood clots, thus maintaining clot integrity and reducing bleeding.

Uses of Texlite 500mg Tablet SR 10s

• Treatment of heavy menstrual bleeding
• Management of nosebleeds
• Prevention of bleeding after surgery

Side effects of Texlite 500mg Tablet SR 10s

• Common side effects: nausea, vomiting, diarrhea
• Serious side effects: consult a doctor if you experience any new or worsening symptoms

Precautions of Texlite 500mg Tablet SR 10s

Texlite 500mg Tablet SR 10s should not be used by individuals with a history of blood clots, such as deep vein thrombosis or pulmonary embolism. It is crucial to consult your healthcare provider before starting this medication to ensure it is safe for you.

How to Take Texlite 500mg Tablet SR 10s

The usage method for Texlite 500mg Tablet SR 10s may vary depending on whether it’s available as a tablet, injection, or topical form. Follow your doctor’s advice for the correct way to use your prescribed form. Typically, the dosage for adults is 1,000 to 1,500 mg taken two to three times a day, with or without food.

Conclusion of Texlite 500mg Tablet SR 10s

Texlite 500mg Tablet SR 10s, containing Tranexamic Acid, is a therapeutic agent used to manage excessive bleeding. Manufactured by Sol Derma Pharmaceuticals Pvt Ltd, this medication is effective in treating conditions like heavy menstrual bleeding and post-surgical bleeding. Always consult your healthcare provider for personalized advice and follow their instructions for optimal results.